News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Judith Balmaña

Articles by Judith Balmaña

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

ByPedram Razavi,Judith Balmaña,Stephen Luen,Mario Campone,Laura Cortesi,Norikazu Masuda,Kyong Hwa Park,Qingyuan Zhang,Emily Nizialek,Cathy Qi,Karen Cui,Sibylle Loibl,Mark Robson, MD,Filipa Lynce

April 22nd 2025

Latest Updated Articles

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)
April 22nd 2025

Trending on CancerNetwork

64 A Phase I/II Study of Pembrolizumab and Anti-CD3 x Anti-HER2 Armed Activated T-Cells in Metastatic Breast Cancer

FDA Accepts BLA for Ozekibart in Unresectable or Metastatic Chondrosarcoma

Analyzing ADC Options Across Metastatic TNBC

CD47 Antibody Combo Shows Meaningful Activity in Previously Untreated AML

Elucidating First-Line SC Mosunetuzumab Benefit in Follicular Lymphoma